Question · asked by 1 review
Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d: Adverse effects
- Population
- People with American cutaneous and mucocutaneous leishmaniasis
- Intervention
- Azithromycin (500 mg 20 ‐ 28 days)
- Comparison
- meglumine antimoniate (15 ‐ 20 mg/kg/d
- Outcome
- Adverse effects
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis Interventions for American cutaneous and mucocutaneous leishmaniasis (2020) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 45 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.